Covalent inhibitors of kras
US-2025154133-A1 · May 15, 2025 · US
Compositions and methods for inhibition of RAS
US12528818B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12528818-B2 |
| Application number | US-202519196683-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 1, 2025 |
| Priority date | Jul 23, 2021 |
| Publication date | Jan 20, 2026 |
| Grant date | Jan 20, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12C mutation) and treating diseases or disorders such as cancers in subjects in need thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A compound selected from: or a pharmaceutically acceptable salt thereof. 2 . A compound having the structure: or a pharmaceutically acceptable salt thereof. 3 . A compound having the structure: or a pharmaceutically acceptable salt thereof. 4 . A compound having the structure: or a pharmaceutically acceptable salt thereof. 5 . A compound of claim 1 , wherein the compound is selected from: 6 . The compound of claim 2 , wherein the compound is 7 . The compound of claim 3 , wherein the compound is 8 . The compound of claim 4 , wherein the compound is 9 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof. 10 . The pharmaceutical composition of claim 9 , wherein the compound is or a pharmaceutically acceptable salt thereof. 11 . The pharmaceutical composition of claim 9 , wherein the compound is or a pharmaceutically acceptable salt thereof. 12 . The pharmaceutical composition of claim 9 , wherein the compound is or a pharmaceutically acceptable salt thereof. 13 . A pharmaceutical composition comprising a compound of claim 5 . 14 . The pharmaceutical composition of claim 13 , wherein the compound is 15 . The pharmaceutical composition of claim 13 , wherein the compound is 16 . The pharmaceutical composition of claim 13 , wherein the compound is
Assignees
Inventors
Classifications
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Ortho-condensed systems · CPC title
Spiro-condensed systems · CPC title
Bridged systems · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12528818B2 cover?
- Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12C mutation) and treating diseases or disorders such as cancers in subjects in need thereof.
- Who is the assignee on this patent?
- Leidos Biomedical Res Inc, L Livermore Nat Security Llc, Theras Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D417/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).